Previous 10 | Next 10 |
PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation PR Newswire - This award recognizes PTC's 25-year legacy in discovering and delivering novel therapies that address the underlying cause of rare diseases - SOUTH PLAINFIELD, N.J. , Feb...
Summary PTCT is a commercial stage small cap surviving on a timely loan. Their revenue stream is overdependent on one franchise. Price is near 52-week highs, reason unknown. PTC Therapeutics ( PTCT ) is a mid-sized rare disease player with 6 approved products and a num...
Summary ClearPoint Neuro is a growth story and should be evaluated as such. I break down some of the growth factors that I consider most important. I also review the company valuation and cash position in explaining how I come to my "Buy" rating. For further de...
Summary Shares of gene therapy concern Design Therapeutics fell 33% after releasing its first-ever data in the treatment of Friedreich’s ataxia on December 7, 2022. The market was disappointed by the lack of increase in FXN protein expression, a possibly unrealistic expectation a...
Summary Shares of genetic muscle disease concern Dyne Therapeutics, Inc. have enjoyed a recent bounce on the back of good news from a rival, more than tripling in price. The recent news somewhat validated/de-risked its oligonucleotide approach to treating muscle diseases, as its first t...
NICE Recommends Reimbursement for Translarna™ PR Newswire - Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J. , Jan. 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: P...
Summary Vir Biotechnology is a commercial-stage immunology company that bases its activity on infectious disease prevention. The agreement with GSK made it possible to obtain large revenues and profits in 2022. A good pipeline allows us to assume high growth in the coming years. ...
PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community PR Newswire - 2023 Program to Focus on Innovation and Transition to Adulthood Initiatives – - Submissions Due March...
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference PR Newswire - ...
PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH PLAINFIELD, N.J. , Jan. 4, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41 s...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....